Shingles Vaccine – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of the shingles vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the number of shingles vaccine-eligible population for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s shingles vaccine forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the shingles vaccine over the forecast period?
All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following shingles vaccine patient populations:
- Vaccine-eligible population.
- Population newly eligible for the vaccine.
Note: Coverage may vary by country and region.
